Favipiravir (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Favipiravir" in Italian language version.

refsWebsite

Global rank Italian rank

18doi.org

2^nd place

7^th place

14nih.gov

4^th place

9^th place

3oadoi.org

799^th place

22^nd place

2theguardian.com

12^th place

32^nd place

1precisionvaccinations.com

low place

1bloomberg.com

99^th place

274^th place

1yna.co.kr

981^st place

2,114^th place

1fujifilm.com.au

low place

1reuters.com

49^th place

129^th place

1chinadaily.com.cn

831^st place

1,223^rd place

1ilfattoquotidiano.it

823^rd place

30^th place

1repubblica.it

78^th place

2^nd place

1aifa.gov.it

low place

6,468^th place

1liberoquotidiano.it

5,457^th place

206^th place

1sciencedirect.com

149^th place

298^th place

1biorxiv.org

5,061^st place

7,234^th place

1harvard.edu

18^th place

104^th place

1diamond.jp

2,938^th place

low place

1cbc.ca

115^th place

387^th place

1rfi.fr

559^th place

1,586^th place

1who.int

195^th place

342^nd place

1clinicaltrials.gov

5,225^th place

5,296^th place

1oup.com

485^th place

613^th place

1cdc.gov

218^th place

774^th place

1pmda.go.jp

6,690^th place

low place

aifa.gov.it

AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull’efficacia, su aifa.gov.it. URL consultato il 22 marzo 2020.

biorxiv.org

(EN) Sangeun Jeon et al., Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs (PDF), su biorxiv.org, p. 5. URL consultato il 23 marzo 2020.

bloomberg.com

Cynthia Koons, Ebola Drug From Japan May Emerge Among Key Candidates, Bloomberg.com, 7 agosto 2014.

cbc.ca

Ebola outbreak: Japan offers anti-influenza drug for treatment |, su cbc.ca, CBC News. URL consultato il 21 marzo 2020.

cdc.gov

(EN) Julia Murphy, Human Rabies — Virginia, 2017, in MMWR. Morbidity and Mortality Weekly Report, vol. 67, 2019, DOI:10.15585/mmwr.mm675152a2. URL consultato il 3 aprile 2020.

chinadaily.com.cn

Potential coronavirus drug approved for marketing - Chinadaily.com.cn, su chinadaily.com.cn. URL consultato il 21 marzo 2020.

clinicaltrials.gov

(EN) Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316 - No Study Results Posted - ClinicalTrials.gov, su clinicaltrials.gov. URL consultato il 22 marzo 2020.

diamond.jp

(JA) 条件付き承認で普及に足かせ富山化学インフル薬の"無念", su diamond.jp. URL consultato il 25 febbraio 2014.

doi.org

dx.doi.org

Delang L, Abdelnabi R, Neyts J, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, in Antiviral Res., vol. 153, May 2018, pp. 85-94, DOI:10.1016/j.antiviral.2018.03.003, PMID 29524445.
Hayden FG, Shindo N, Influenza virus polymerase inhibitors in clinical development, in Curr. Opin. Infect. Dis., vol. 32, n. 2, April 2019, pp. 176-186, DOI:10.1097/QCO.0000000000000532, PMC 6416007, PMID 30724789.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020 Feb DOI: 10.1038/d41573-020-00016-0
(EN) Qingxian Cai, Minghui Yang e Dongjing Liu, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, in Engineering, 18 marzo 2020, DOI:10.1016/j.eng.2020.03.007. URL consultato il 2020-03 21.
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques, in PLoS Medicine, vol. 15, n. 3, March 2018, pp. e1002535, DOI:10.1371/journal.pmed.1002535, PMC 5870946, PMID 29584730.
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y, Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells, in The Journal of Antimicrobial Chemotherapy, vol. 64, n. 4, October 2009, pp. 741-46, DOI:10.1093/jac/dkp274, PMC 2740635, PMID 19643775.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J, Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), in Molecular Pharmacology, vol. 84, n. 4, October 2013, pp. 615-29, DOI:10.1124/mol.113.087247, PMID 23907213.
Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD, T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections, in Antiviral Research, vol. 82, n. 3, June 2009, pp. 95-102, DOI:10.1016/j.antiviral.2009.02.198, PMID 19428599.
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase, in PLOS ONE, vol. 8, n. 7, 2013, pp. e68347, Bibcode:2013PLoSO...868347J, DOI:10.1371/journal.pone.0068347, PMC 3707847, PMID 23874596.
Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA, T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, in Journal of Virology, vol. 87, n. 7, April 2013, pp. 3741-51, DOI:10.1128/JVI.02346-12, PMC 3624194, PMID 23325689.
Furuta Y, Komeno T, Nakamura T, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, in Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci., vol. 93, n. 7, 2017, pp. 449-463, DOI:10.2183/pjab.93.027, PMC 5713175, PMID 28769016. URL consultato il 24 marzo 2020.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, in Antiviral Research, vol. 100, n. 2, November 2013, pp. 446-54, DOI:10.1016/j.antiviral.2013.09.015, PMC 3880838, PMID 24084488.
Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL, Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever, in PLoS Neglected Tropical Diseases, vol. 8, n. 4, April 2014, pp. e2790, DOI:10.1371/journal.pntd.0002790, PMC 3983105, PMID 24722586.
Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP, Zika Virus: Where Is the Treatment?, in Current Treatment Options in Infectious Diseases, vol. 8, n. 3, 2016, pp. 208-11, DOI:10.1007/s40506-016-0083-7, PMC 4969322, PMID 27547128.
Tatiana Baranovich, Sook-San Wong e Jianling Armstrong, T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, in Journal of Virology, vol. 87, n. 7, 2013-04, pp. 3741-3751, DOI:10.1128/JVI.02346-12. URL consultato il 3 aprile 2020.
(EN) Kentaro Yamada, Kazuko Noguchi e Takashi Komeno, Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis, in The Journal of Infectious Diseases, vol. 213, n. 8, 15 aprile 2016, pp. 1253-1261, DOI:10.1093/infdis/jiv586. URL consultato il 3 aprile 2020.
(EN) Julia Murphy, Human Rabies — Virginia, 2017, in MMWR. Morbidity and Mortality Weekly Report, vol. 67, 2019, DOI:10.15585/mmwr.mm675152a2. URL consultato il 3 aprile 2020.
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK, Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses, in Antimicrobial Agents and Chemotherapy, vol. 62, n. 8, August 2018, pp. e00766–18, DOI:10.1128/AAC.00766-18, PMC 6105843, PMID 29891600.

fujifilm.com.au

Taiwan's government organization decides to stockpile Fujifilm's anti-influenza drug “Avigan® Tablet” —Fujifilm supplies Avigan® Tablet to Taiwan—, su fujifilm.com.au. URL consultato il 21 marzo 2020.

harvard.edu

adsabs.harvard.edu

Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase, in PLOS ONE, vol. 8, n. 7, 2013, pp. e68347, Bibcode:2013PLoSO...868347J, DOI:10.1371/journal.pone.0068347, PMC 3707847, PMID 23874596.

ilfattoquotidiano.it

Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci sono scarse evidenze scientifiche su efficacia", su Il Fatto Quotidiano, 22 marzo 2020. URL consultato il 22 marzo 2020.

liberoquotidiano.it

Coronavirus, il colosso che produce Avigan: "I test in Italia ci preoccupano, meglio non farlo" – Libero Quotidiano, su liberoquotidiano.it, 24 marzo 2020. URL consultato il 24 marzo 2020.

nih.gov

ncbi.nlm.nih.gov

Delang L, Abdelnabi R, Neyts J, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, in Antiviral Res., vol. 153, May 2018, pp. 85-94, DOI:10.1016/j.antiviral.2018.03.003, PMID 29524445.
Hayden FG, Shindo N, Influenza virus polymerase inhibitors in clinical development, in Curr. Opin. Infect. Dis., vol. 32, n. 2, April 2019, pp. 176-186, DOI:10.1097/QCO.0000000000000532, PMC 6416007, PMID 30724789.
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques, in PLoS Medicine, vol. 15, n. 3, March 2018, pp. e1002535, DOI:10.1371/journal.pmed.1002535, PMC 5870946, PMID 29584730.
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y, Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells, in The Journal of Antimicrobial Chemotherapy, vol. 64, n. 4, October 2009, pp. 741-46, DOI:10.1093/jac/dkp274, PMC 2740635, PMID 19643775.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J, Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), in Molecular Pharmacology, vol. 84, n. 4, October 2013, pp. 615-29, DOI:10.1124/mol.113.087247, PMID 23907213.
Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD, T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections, in Antiviral Research, vol. 82, n. 3, June 2009, pp. 95-102, DOI:10.1016/j.antiviral.2009.02.198, PMID 19428599.
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase, in PLOS ONE, vol. 8, n. 7, 2013, pp. e68347, Bibcode:2013PLoSO...868347J, DOI:10.1371/journal.pone.0068347, PMC 3707847, PMID 23874596.
Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA, T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, in Journal of Virology, vol. 87, n. 7, April 2013, pp. 3741-51, DOI:10.1128/JVI.02346-12, PMC 3624194, PMID 23325689.
Furuta Y, Komeno T, Nakamura T, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, in Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci., vol. 93, n. 7, 2017, pp. 449-463, DOI:10.2183/pjab.93.027, PMC 5713175, PMID 28769016. URL consultato il 24 marzo 2020.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, in Antiviral Research, vol. 100, n. 2, November 2013, pp. 446-54, DOI:10.1016/j.antiviral.2013.09.015, PMC 3880838, PMID 24084488.
Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL, Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever, in PLoS Neglected Tropical Diseases, vol. 8, n. 4, April 2014, pp. e2790, DOI:10.1371/journal.pntd.0002790, PMC 3983105, PMID 24722586.
Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP, Zika Virus: Where Is the Treatment?, in Current Treatment Options in Infectious Diseases, vol. 8, n. 3, 2016, pp. 208-11, DOI:10.1007/s40506-016-0083-7, PMC 4969322, PMID 27547128.
Tatiana Baranovich, Sook-San Wong e Jianling Armstrong, T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, in Journal of Virology, vol. 87, n. 7, 2013-04, pp. 3741-3751, DOI:10.1128/JVI.02346-12. URL consultato il 3 aprile 2020.
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK, Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses, in Antimicrobial Agents and Chemotherapy, vol. 62, n. 8, August 2018, pp. e00766–18, DOI:10.1128/AAC.00766-18, PMC 6105843, PMID 29891600.

oadoi.org

Delang L, Abdelnabi R, Neyts J, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, in Antiviral Res., vol. 153, May 2018, pp. 85-94, DOI:10.1016/j.antiviral.2018.03.003, PMID 29524445.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J, Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), in Molecular Pharmacology, vol. 84, n. 4, October 2013, pp. 615-29, DOI:10.1124/mol.113.087247, PMID 23907213.
Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD, T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections, in Antiviral Research, vol. 82, n. 3, June 2009, pp. 95-102, DOI:10.1016/j.antiviral.2009.02.198, PMID 19428599.

oup.com

academic.oup.com

(EN) Kentaro Yamada, Kazuko Noguchi e Takashi Komeno, Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis, in The Journal of Infectious Diseases, vol. 213, n. 8, 15 aprile 2016, pp. 1253-1261, DOI:10.1093/infdis/jiv586. URL consultato il 3 aprile 2020.

pmda.go.jp

(EN) www.pmda.go.jp (PDF), su pmda.go.jp. URL consultato il 24 marzo 2020.

precisionvaccinations.com

Japan Testing Flu Medication Treatment Against COVID-19 Disease — Precision Vaccinations, su precisionvaccinations.com. URL consultato il 21 marzo 2020.

repubblica.it

Covid-19: Speranza, “Aifa procede su sperimentazione Avigan”, su la Repubblica, 23 marzo 2020. URL consultato il 3 aprile 2020.

reuters.com

BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus. Reuters Healthcare, February 16, 2020.

rfi.fr

French nurse cured of Ebola, su rfi.fr. URL consultato il 21 marzo 2020.

sciencedirect.com

(EN) Qingxian Cai, Minghui Yang e Dongjing Liu, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, in Engineering, 18 marzo 2020, DOI:10.1016/j.eng.2020.03.007. URL consultato il 2020-03 21.

theguardian.com

(EN) Justin McCurry, Japanese flu drug 'clearly effective' in treating coronavirus, says China, in The Guardian, 18 marzo 2020. URL consultato il 21 marzo 2020.
Japanese flu drug 'clearly effective' in treating coronavirus, says China | World news | The Guardian, su theguardian.com. URL consultato il 21 marzo 2020.

who.int

WHO | Ethical considerations for use of unregistered interventions for Ebola virus disease, su who.int, WHO. URL consultato il 21 marzo 2020.

yna.co.kr

en.yna.co.kr

(EN) S. Korea not to use Japan's Avigan as coronavirus drug | Yonhap News Agency, su en.yna.co.kr, Yonhap News Agency. URL consultato il 22 marzo 2020.